Matthew Balmforth

Dr. Matthew Balmforth

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
BPBenjamin T. Porebski
Benjamin T. Porebski
MBMatthew Balmforth
Matthew Balmforth
GBGareth Browne
Gareth Browne
ARAidan Riley
Aidan Riley
KJKiarash Jamali
Kiarash Jamali
PHPhilipp Holliger
Philipp Holliger
Developing therapeutic antibodies is laborious and costly. Here we report a method for antibody discovery that leverages the Illumina HiSeq platform to, within 3 days, screen in the order of 10 8 antibody–antigen interactions. The method, which we named ‘deep screening’, involves the clustering and sequencing of antibody libraries, the conversion of the DNA clusters into complementary RNA clusters covalently linked to the instrument’s flow-cell surface on the same location, the in situ translation of the clusters into antibodies tethered via ribosome display, and their screening via fluorescently labelled antigens. By using deep screening, we discovered low-nanomolar nanobodies to a model antigen using 4 × 10 6 unique variants from yeast-display-enriched libraries, and high-picomolar single-chain antibody fragment leads for human interleukin-7 directly from unselected synthetic repertoires. We also leveraged deep screening of a library of 2.4 × 10 5 sequences of the third complementarity-determining region of the heavy chain of an anti-human epidermal growth factor receptor 2 (HER2) antibody as input for a large language model that generated new single-chain antibody fragment sequences with higher affinity for HER2 than those in the original library.

12 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
RARalph Adams
Ralph Adams
CJCallum Joyce
Callum Joyce
MKMikhail Kuravskiy
Mikhail Kuravskiy
KHKatriona Harrison
Katriona Harrison
ZAZainab Ahdash
Zainab Ahdash
AMAlex Macpherson
Alex Macpherson
Background: Serum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments described to date and versatile tools for protein engineering.Methods: Here, we used phage display of bovine immune material to derive knob domains against human and rodent serum albumins. These were used to engineer bispecific Fab fragments, by using the framework III loop as a site for knob domain insertion. Results: By this route, neutralisation of the canonical antigen (TNFα) was retained but extended pharmacokinetics in-vivo were achieved through albumin binding. Structural characterisation revealed correct folding of the knob domain and identified broadly common but non-cross-reactive epitopes. Additionally, we show that these albumin binding knob domains can be chemically synthesised to achieve dual IL-17A neutralisation and albumin binding in a single chemical entity. Conclusions: This study enables antibody and chemical engineering from bovine immune material, via an accessible discovery platform.

13 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKristian Hollingsworth
Kristian Hollingsworth
AMAntonio Di Maio
Antonio Di Maio
SRSarah-Jane Richards
Sarah-Jane Richards
JVJean-Baptiste Vendeville
Jean-Baptiste Vendeville
DWDavid E. Wheatley
David E. Wheatley
BLBruno Linclau
Bruno Linclau
Glycan-mediated interactions play a crucial role in biology and medicine, influencing signalling, immune responses, and disease pathogenesis. However, the use of glycans in biosensing and diagnostics is limited by cross-reactivity, as certain glycan motifs can be recognised by multiple biologically distinct protein receptors. To address this specificity challenge, we report the enzymatic synthesis of a 150-member library of site-specifically fluorinated Lewisx analogues (‘glycofluoroforms’) using naturally occurring enzymes and fluorinated monosaccharides. Subsequent incorporation of a subset of these glycans into nanoparticles or a microarray revealed a striking spectrum of distinct binding intensities across different proteins that recognise Lewisx. Notably, we show that for two proteins with unique binding sites for Lewisx, glycofluoroforms exhibited enhanced binding to one protein, whilst reduced binding to the other, with selectivity governed by fluorination patterns. We finally showcase the potential diagnostic utility of this approach in glycofluoroform-mediated bacterial toxin detection by lateral flow.

26 September 2021 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MBMatthew Balmforth
Matthew Balmforth
JHJessica Haigh
Jessica Haigh
VKVajinder Kumar
Vajinder Kumar
WDWenyue Dai
Wenyue Dai
CTChristian Tiede
Christian Tiede
Bruce TurnbullBruce Turnbull
Bruce Turnbull

28 January 2016 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
PMPhilip M. Morrison
Philip M. Morrison
MBMatthew Balmforth
Matthew Balmforth
SNSamuel W. Ness
Samuel W. Ness
DWDaniel J. Williamson
Daniel J. Williamson
MRMichael D. Rugen
Michael D. Rugen
MWMichael A. Webb
Michael A. Webb

28 May 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
CRCatherine E. Rowland
Catherine E. Rowland
HNHector Newman
Hector Newman
TMTazmin T. Martin
Tazmin T. Martin
RDRachel Dods
Rachel Dods
NBNikolaos Bournakas
Nikolaos Bournakas
MDMichael J. Dawson
Michael J. Dawson
Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of bicyclic peptide (Bicycle®) inhibitors of E. coli PBP3 (EcPBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent, to our knowledge, a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors. This work demonstrates an approach to rapidly find binders to antimicrobial targets, combined with an entry mechanism to provide access to the Gram negative cell.